Myeloid

​​​

Protocols

Myeloproliferative Neoplasms (MPN)

LKANAG

Anagrelide as second-line treatment of thrombocytosis related to myeloproliferative disorders

ULKMFFED

Treatment of Symptomatic Myelofibrosis with Fedratinib

LKMFRUX

Treatment of Symptomatic Myelofibrosis with Ruxolitinib​

LKPCVRUX

Treatment of Polycythemia Vera with Ruxolitinib​

LKPEGIFN

Peginterferon Alfa-2a Therapy of Chronic Myeloid Neoplasms and Hypereosinophilic Syndrome​

ULK0 Ropeginterferon alfa 2b

Interim Protocol for Ropeginterferon Alfa-2b Therapy of Chronic Myeloid Neoplasms and Hypereosinophilic Syndrome​

UMLASMAVA

Treatment of Advanced Systemic Mastocytosis using Avapritinib

UMLMFMOM

Treatment of Symptomatic Myelofibrosis with Momelotinib

Back to top

Myelodysplastic Syndrome (MDS)

LKMDSA

Therapy of Myelodysplastic Syndrome using Azacitidine

ULKMDSDC

LKMDSL

Therapy of Myelodysplastic Syndrome using Lenalidomide

Back to top

Chr​onic Myeloid Leukemia (CML)

LKCMLA

Treatment of Chronic Myeloid Leukemia using Asciminib

LKCMLB

Treatment of Chronic Myeloid Leukemia Using Bosutinib

LKCMLD

Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Dasatinib

LKCMLI

Therapy for Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Imatinib

LKCMLN

Treatment of Chronic Myeloid Leukemia Using Nilotinib

ULKCMLP

Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Ponatinib

Back to top

Acute Myeloid Leukemia (AML)

ULKAMLAVEN

Therapy of Acute Myeloid Leukemia using azaCITIDine and Venetoclax

LKAMLCYT

Therapy of Acute Myeloid Leukemia Using Low dose Cytarabine

ULKAMLGIL

Therapy of Relapsed or Refractory FLT3+ Acute Myeloid Leukemia using Gilteritinib

Back to top

​
Funding algorithm
Terms of use
​The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. 

Use of these documents is at your own risk and is subject to BC Cancer's terms of use.


Tab Heading